Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 210-219

  Christadoss, Premkumar ^a   Tüzün, Erdem ^b   Li, Jing ^a   Saini, Shamsher S ^a   Yang, Huan ^c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Autoimmunity; Complement; Experimental autoimmune myasthenia gravis; Immune complex; Myasthenia gravis

Indexed keywords

CHOLINERGIC RECEPTOR; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT MEMBRANE ATTACK COMPLEX; INTERLEUKIN 6; T LYMPHOCYTE RECEPTOR;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CELL PROLIFERATION; COMPLEMENT CLASSICAL PATHWAY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE RESISTANCE; DISEASE SEVERITY; IMMUNE RESPONSE; LYMPH NODE CELL; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN INTERACTION;

MUS;

EID: 45249122485     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.009     Document Type: Conference Paper

References (39)

1. Vincent, A. 2006. Immunology of disorders of neuromuscular transmission. Acta Neurol. Scand. Suppl. 183 : 1 7.
2. Conti-Fine, B.M., M. Milani & H.J. Kaminski. 2006. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 : 2843 2854.
3. Vincent, A. & D.B. Drachman. 2000. Myasthenia gravis. Adv. Neurol. 88 : 159 188.
4. Tzartos, S.J., T. Barkas, M.T. Cung, et al. 1998. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev. 163 : 89 120.
5. Christadoss, P., M. Poussin & C. Deng. 2000. Animal models of myasthenia gravis. Clin. Immunol. 94 : 75 87.
6. Tüzün, E., B.G. Scott, E. Goluszko, et al. 2003. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171 : 3847 3854.
7. Scott, B.G., H. Yang, E. Tüzün, et al. 2004. ICOS is essential for the development of experimental autoimmune myasthenia gravis. J. Neuroimmunol. 153 : 16 25.
8. Tüzün, E., J. Li, S.S. Saini, et al. 2007. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J. Neuroimmunol. 182 : 167 176.
9. Tüzün, E., S.S. Saini, H. Yang, et al. 2006. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis. J. Neuroimmunol. 174 : 157 167.
10. Nastuk, W.L., O.J. Plescia & K.E. Osserman. 1960. Changes in serum complement activity in patients with myasthenia gravis. Proc. Soc. Exp. Biol. Med. 105 : 177 184.
11. Casali, P., P. Borzini & C. Zanussi. 1976. Immune complexes in myasthenia gravis. Lancet 2 : 378.
12. Engel, A.G., K. Sahashi & G. Fumagalli. 1981. The immunopathology of acquired myasthenia gravis. Ann. N Y. Acad. Sci. 377 : 158 174.
13. Sahashi, K., A.G. Engel, E.H. Lambert, et al. 1980. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J. Neuropathol. Exp. Neurol. 39 : 160 172.
14. Tüzün, E., S.S. Saini, S. Ghosh, et al. 2006. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul. Disord. 16 : 137 143.
15. Graus, Y.M., J.J. Verschuuren & F. Spaans, et al. 1993. Age-related resistance to experimental autoimmune myasthenia gravis in rats. J. Immunol. 150 : 4093 4103.
16. Yang, H., E. Tüzün, D. Alagappan, et al. 2005. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J. Immunol. 175 : 2018 2025.
17. Deng, C., E. Goluszko, E. Tüzün, et al. 2002. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 169 : 1077 1083.
18. Karachunski, P.I., N.S. Ostlie, C. Monfardini, et al. 2000. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 164 : 5236 5244.
19. Poussin, M.A., E. Goluszko, J.U. Franco, et al. 2002. Role of IL-5 during primary and secondary immune response to acetylcholine receptor. J. Neuroimmunol. 125 : 51 58.
20. Piddlesden, S.J., S. Jiang, J.L. Levin, et al. 1996. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 71 : 173 177.
21. Lennon, V.A., M.E. Seybold, J.M. Lindstrom, et al. 1978. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147 : 973 983.
22. Biesecker, G. & C.M. Gomez. 1989. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immunol. 142 : 2654 2659.
23. Christadoss, P. 1988. C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140 : 2589 2592.
24. Carroll, M. 1999. Negative selection of self-reactive B lymphocytes involves complement. Curr. Top. Microbiol. Immunol. 246 : 21 27.
25. Romi, F., E.K. Kristoffersen, J.A. Aarli, et al. 2005. The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J. Neuroimmunol. 158 : 191 194.
26. Nielsen, C.H., L. Hegedus & R.G. Leslie. 2004. Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. Eur. J. Immunol. 34 : 263 272.
27. Melms, A., R. Weissert, W.E. Klinkert, et al. 1993. Specific immune complexes augment in vitro acetylcholine receptor-specific T-cell proliferation. Neurology 43 : 583 588.
28. Waggoner, S.N., M.W. Cruise, R. Kassel, et al. 2005. gC1q receptor ligation selectively down-regulates human IL-12 production through activation of the phosphoinositide 3-kinase pathway. J. Immunol. 175 : 4706 4714.
29. Tüzün, E., B.G. Scott, H. Yang, et al. 2004. Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice. J. Immunol. 172 : 5743 5752.
30. Mathai, A., C. Sarada & V.V. Radhakrishnan. 2000. Significance of circulating immune complexes in myasthenia gravis. Indian J. Med. Res. 111 : 180 183.
31. Dijstelbloem, H.M., J.G. van de Winkel & C.G. Kallenberg. 2001. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol. 22 : 510 516.
32. Zhou, A.Q., M.J. Herriott & R.W. Leu. 1991. Kinetics of the biosynthesis of complement subcomponent C1q by murine macrophages: LPS, immune complexes, and zymosan alone and in combination with interferon-gamma. J. Leukoc. Biol. 50 : 453 463.
33. Ronnelid, J., A. Tejde, L. Mathsson, et al. 2003. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann. Rheum. Dis. 62 : 37 42.
34. Stapp, J.M., V. Sjoelund, H.A. Lassiter, et al. 2005. Recombinant rat IL-1beta and IL-6 synergistically enhance C3 mRNA levels and complement component C3 secretion by H-35 rat hepatoma cells. Cytokine 30 : 78 85.
35. Poussin, M.A., E. Goluszko, T.K. Hughes, et al. 2000. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. J. Neuroimmunol. 111 : 152 160.
36. Luckman, S.P., G.O. Skeie, G. Helgeland, et al. 2006. Morphological effects of myasthenia gravis patient sera on human muscle cells. Muscle Nerve 33 : 93 103.
37. Tüzün, E., J. Li, N. Wanasen, et al. 2006. Immunization of mice with T cell-dependent antigens promotes IL-6 and TNF-alpha production in muscle cells. Cytokine 35 : 100 106.
38. Tüzün, E., M.N. Meriggioli, J. Rowin, et al. 2005. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J. Autoimmun. 24 : 261 268.
39. Rowin, J., M.N. Meriggioli, E. Tüzün, et al. 2004. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 63 : 2390 2392.